The RAP Program is conducting a research study of the antipsychotic medication Aripiprazole.
This drug has been approved for treating symptoms associated with schizophrenia and is
associated with fewer side effects. This study will explore how well Aripiprazole treats
symptoms of early-onset psychotic disorders as well as symptoms that may indicate risk for
such disorders, including unusual thoughts, suspiciousness, perceptual abnormalities, social
isolation, and sudden changes in functioning.